Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02530255 · ClinicalTrials.gov registry record · NA

Telomerase Activator and Retinal Amyloid

A NA study of Alzheimer Disease, sponsored by Chippewa Valley Eye Clinic.

Completed
Registry status
NA
Development phase
48
Enrollment target
1
Study location

NCT02530255 is a NA study of Alzheimer Disease that has completed, run by Chippewa Valley Eye Clinic. The registered enrollment target is 48 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02530255, a NA study of Alzheimer Disease, has completed, sponsored by Chippewa Valley Eye Clinic.

COMPLETED
Registry status
NA
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

A method of detecting amyloid in the retina has been developed. A specially designed retinal camera will directly visualze and record retinal amyloid and via image processing will generate a number: the retinal amyloid index (RAI). The amount of retinal amyloid correlates with cerebral amyloid and has a predictive value in Alzheimer's disease. Telomere attrition accounts for cellular aging and is felt to have a pivotal role in Alzheimer's disease. The investigators plan to screen individuals to select those having retinal amyloid then evaluate an oral telomerase activator to determine if its use can alter the RAI over time compared to placebo.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT cycloastragenol
  • DIETARY_SUPPLEMENT placebo (for cycloastragenol)

Study Locations (1)

Wisconsin

  • Chippewa Valley Eye Clinic - Eau Claire

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2016-12-01
Est. Completion 2018-12-31
Phase NA

Sponsor

Chippewa Valley Eye Clinic

1 total trials

What the Registry Record Tells You About NCT02530255

The ClinicalTrials.gov registry entry for NCT02530255 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The listed sponsor is Chippewa Valley Eye Clinic, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which cycloastragenol is the first listed.

NCT02530255 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT02530255 about?

NCT02530255 is a clinical study titled "Telomerase Activator and Retinal Amyloid". A method of detecting amyloid in the retina has been developed. A specially designed retinal camera will directly visualze and record retinal amyloid and via image processing will generate a number: the retinal amyloid index (RAI). The amount of retinal amyloid correlates with cerebral amyloid and h...

What is the current status of trial NCT02530255?

This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2016-12-01. Estimated completion is 2018-12-31.

What conditions does trial NCT02530255 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT02530255?

The interventions under investigation include: cycloastragenol (DIETARY_SUPPLEMENT), placebo (for cycloastragenol) (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02530255?

This trial is sponsored by Chippewa Valley Eye Clinic, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02530255 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.